ArticleCurrent treatment options in cardiovascular medicine2016
Intracranial Hemorrhage Risk in the Era of Antithrombotic Therapies for Ischemic Stroke.
Article in Current treatment options in cardiovascular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Extensive Intracerebral Hemorrhage Involving Basal Ganglia and Frontal Lobe With Intraventricular and Subarachnoid Extension in a Triplet Pregnancy Following In Vitro Fertilization: A Case Report and Review.Clinical case reports · 2026Article
- Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions.Circulation research · 2022Review
- The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention.Handbook of clinical neurology · 2021Article
- Prediction of amyloid β PET positivity using machine learning in patients with suspected cerebral amyloid angiopathy markers.Scientific reports · 2020Article
- Microangiopathy underlying mixed-location intracerebral hemorrhages/microbleeds: A PiB-PET study.Neurology · 2019Article
- Updates on Prevention of Hemorrhagic and Lacunar Strokes.Journal of stroke · 2018Article
- Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.Current neurology and neuroscience reports · 2018Review
- Mixed-location cerebral hemorrhage/microbleeds: Underlying microangiopathy and recurrence risk.Neurology · 2018Article
- Nonpharmacological Management of Atrial Fibrillation in Patients at High Intracranial Hemorrhage Risk.Stroke · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementIntracranial hemorrhage (ICH) is the most feared complication of antithrombotic medication use for the treatment and prevention of ischemic stroke. The risk of ICH while on blood thinners varies not only among different types of antithrombotics but also for the same agent used in different patient populations. Individual patients have different susceptibilities to ICH mostly due to the presence or absence of bleeding-prone cerebral pathologies such as cerebral amyloid angiopathy or hypertensive small vessel disease. The recent development and FDA approval of novel anticoagulants may lead to increased safety when compared to previously used medications, and the emergence of nonpharmacologic approaches may obviate the need for long-term anticoagulant strategies in certain clinical situations, such as left atrial appendage closure for stroke prevention in atrial fibrillation. As such, blanket recommendations for antithrombotic choice cannot be justified. Good practices in vascular neurology dictate combining all available data in order to choose the treatment that has the best risk-benefit ratio for each individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.